Other researchers have proposed using AA-PLGA NPs for the treatment of glioblastoma and found that modifying AA-PLGA NPs with transferrin (Tf) can prolong the release time of PLGA NPs (82% release of AA-PLGA NPs within 72 h, Tf-AA-PLGA NPs release 40%), while also enhancing antitumor activity (IC50 values for AA-PLGA NPs and Tf-AA-PLGA NPs against U87 cells were 66 ± 2 μM, 52 ± 7 μM), and reduce the toxicity of AA to normal cells (IC50: AA-PLGA NPs = 83 ± 13 μM; Tf-AA-PLGA NPs = 199 ± 1 μM) [12]. Here, TEAD1 is linked to glioblastoma.